Entering text into the input field will update the search result below

CTI BioPharma up 18% on positive results for pacritinib in rare blood cancer

Jun. 01, 2015 10:13 AM ETCTI BioPharma Corp. (CTIC) StockBy: Douglas W. House, SA News Editor8 Comments
  • CTI BioPharma (NASDAQ:CTIC +17.5%) jumps in early trading in response to its announcement at ASCO (abstract #LBA7006) that patients with myelofibrosis treated with its lead product candidate, pacritinib, in a Phase 3 trial called PERSIST-1 met the primary efficacy endpoint of a statistically significant reduction in spleen volume compared to baseline at week 24. The results were originally reported in March.
  • Fast Track-designated pacritinib, an oral tyrosine kinase inhibitor, is being co-developed with Baxter International (BAX -0.2%). Tyrosine kinase is an enzyme that serves as an "on/off" switch in many cellular functions. If stuck in the "on" position, unregulated cell growth occurs.
  • Previously: CTI Bio up 19% premarket on Phase 3 results (March 9)

Recommended For You

Related Stocks

SymbolLast Price% Chg
CTIC--
CTI BioPharma Corp.